66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Poster

Halls G-H (San Diego Convention Center)

2054

Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Sara El Ashkar, PhD¹, Lorena Kallal²^*, Kavita Raman²^*, Ranjeet Prasad Dash²^*, Nirav Shah²^*, Lore Delbroek¹^*, Lénárd Kertész¹^*, Heleen Van Acker¹^*, Steffie Junius¹^*, Ivo Cornelissen¹^*, Surendar Arumugam¹^*, Lauren Gerloff²^*, Kathryn Bradford²^*, E. Christine Pietsch, PhD³, Leopoldo Luistro, PhD²^*, Bethany Mattson, PhD²^*, Christina Guttke, PhD⁴^*, Karim Safer²^*, Janine Arts, PhD⁵^*, Sonal Patel, PhD⁶^* and Ulrike Philippar, PhD¹

¹Janssen Research & Development, Beerse, Belgium
²Janssen Research & Development, Spring House, PA
³Janssen Research and Development, Spring House, PA
⁴Janssen Research & Development, LLC, Spring House, PA
⁵Janssen Scientific Innovation Oncology, Beerse, Belgium
⁶Janssen Scientific Innovation Oncology, London, United Kingdom

2055

CIB315: An Allogeneic, Off-the-Shelf Anti-GPRC5D iPSC-Derived CAR-NK Product Targeting Multiple Myeloma

Jiayin Yang, PhD^1,2, Lixiang Jiang²^*, Zhibin Zhu²^*, Yubo Yan²^*, Jian Fu²^* and Mingjun Wei²^*

¹Cell Inspire Therapeutics, Shenzhen, China
²Cell Inspire Biotechnology, Shenzhen, China

2056

Developing Novel Cell Therapy Strategies to Convert Macrophage Programming and Induce Synergistic, Multicellular Immunity Against AML

Ryma Toumi, PhD¹^*, Simonne Guenette¹^*, Edison Chiu²^*, Aitong Ruan¹^*, Shannon Oda, PhD¹ and Amber Alcorn¹^*

¹Seattle Children's Research Institute, Seattle, WA
²Seattle Children's Research Institute, seattle, WA

2057

Tumor-Primed CD3⁺CD56⁺natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Ji Hyun Lee, MD, PhD¹, Seok-Ho Kim²^*, Junsang Doh³^*, Duck Cho⁴^*, Jeong-a Kim²^*, Sung Yong Oh⁵^*, Sung-Hyun Kim, MD⁶^* and Juheon Lee²^*

¹Dong-A University College of Medicine, Busan, South Korea
²Department of Health Sciences, The Graduate School of Dong-A University, Busan, Korea, Republic of (South)
³Department of Materials Science and Engineering, College of Engineering, Seoul National University, Seoul, Korea, Republic of (South)
⁴Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁵Dong-A University Hospital, Busan, Korea, Republic of (South)
⁶Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea, Republic of (South)

2058

Development of a Novel Allogeneic Super-Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Hanlu Wang¹^*, Li Liu¹^*, Chao Zhang¹^*, Junxiao Gao¹^*, Lulu Lv, PhD²^* and Li Zhou, MD¹^*

¹Juventas Cell Therapy Ltd., Shanghai, China
²Juventas Cell Therapy Ltd, Tianjin, China

2059

Venetoclax Enhances Human Γδt Cells Anti-Leukemia Immunity through Metabolic Reprogramming

Chen Xingchi^1,2,3^*, Guangyu Sun^1,2,3^*, Yinqiang Sui⁴^*, Weiwei Ma⁴^*, Yonghui Zhang^5,6^* and Xiaoyu Zhu^1,2,3

¹Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
²Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China
³Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
⁴UnicetBio.Co.,Ltd, Beijing, China
⁵Tsinghua-Peking Center for Life Sciences, State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
⁶Tsinghua-Peking Center for Life Sciences, School of Pharmaceutical Science,Tsinghua University, Beijing, China

2060

Bispecific T Cell Engager with Trbc-Targeting Antibody Against Effector T Cells for the Treatment of T Cell Malignancy

Tsubasa Chikada¹^*, Hikari Asano, MS¹^*, Madoka Terashima, MS¹^*, Toshiyuki Tsuchiya, PhD¹^*, Yuuma Kabumoto, MS¹^*, Go Okita, MS¹^*, Toshiaki Takahashi, MS¹^*, Hiroshi Nakakubo, PhD¹^*, Ryouko Mieno, MS²^*, Yuji Ito, MS²^*, Takayoshi Fukushima, MS²^* and Yoji Ishida, MD¹

¹Shinkiba Laboratory, Meiji Seika Pharma Co., Ltd, Tokyo, Japan
²Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Kanagawa, Japan

2061

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, PhD, MSc, BSc¹^*, Paula Maguire, PhD¹^*, Jiwon Yang, PhD²^*, James G Keck³^*, Laura Maher¹^*, Mark Graham⁴^*, Martin F Kaiser, MD^5,6, Emma Searle, MD, PhD⁷^* and Mark Sumeray, MD¹^*

¹Poolbeg Pharma, Dublin, Ireland
²Innovation & Product Development, The Jackson Laboratory, Sacramento, CA
³Innovation & Product Development, The Jackson Laboratory Sacramento, Sacramento, CA
⁴MG Toxicology Consultancy, Leicestershire, United Kingdom
⁵The Royal Marsden NHS Foundation Trust, London, United Kingdom
⁶The Institute of Cancer Research, Sutton, United Kingdom
⁷The Christie NHS Foundation Trust, Manchester, United Kingdom

2062

Vididencel, a Leukemia-Derived Dendritic Cell Vaccine, Acts Synergistically with Azacitidine/Venetoclax Treatment in a Preclinical AML Model

Haoxiao Zuo, PhD¹^*, Calum Leitch, PhD^2,3^*, Jorn Kaspers, MSc¹^*, Mihaela Popa, DVM^2,3^*, Alex Karlsson-Parra, MD, PhD¹^*, Erik Manting, PhD¹^*, Jeroen Rovers, MD, PhD¹^*, Bjorn T. Gjertsen, MD^4,5,6, Emmet McCormack, PhD^2,5,7^* and Satwinder Kaur Singh, PhD⁸^*

¹Mendus AB, Stockholm, Sweden
²Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
³KinN Therapeutics AS, Bergen, Norway
⁴KG Jebsen Centre for Myeloid Blood Cancer CMYC, University of Bergen, Bergen, Norway
⁵Department of Medicine, Hematology section, Haukeland University Hospital, Bergen, Norway
⁶Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
⁷Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway
⁸Mendus AB, Stockholm, AL, Netherlands

2063

Optimizing Chimeric Antigen Receptor Endodomains for Effector Function and Cell Expansion in iPSC-Derived T-Cell Therapies

Chris Dower, Ph.D.^*, Sean Heron^*, Andrew Devaney, M.S.^*, John Wheeler, Ph.D.^*, Amanda Naso, B.S.^*, Wisam Mohamed, M.S.^*, Michael Naso, Ph.D.^* and Jill Carton^*

Century Therapeutics, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.P1.34 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I